Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

Stock Information for Silo Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Silo Pharma Inc.

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.